Live Price Coverage: Could Ritter Pharmaceuticals Inc Crash Even More? The Stock Had Another Big Decline Today

Live Price Coverage: Could Ritter Pharmaceuticals Inc Crash Even More? The Stock Had Another Big Decline Today

The stock of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) is a huge mover today! The stock decreased 6.73% or $0.15 on November 4, hitting $2.08. About 182,712 shares traded hands. Ritter Pharmaceuticals Inc (NASDAQ:RTTR) has risen 88.98% since April 4, 2016 and is uptrending. It has outperformed by 87.89% the S&P500.
The move comes after 7 months negative chart setup for the $22.13M company. It was reported on Nov, 4 by Barchart.com. We have $1.87 PT which if reached, will make NASDAQ:RTTR worth $2.21M less.

Analysts await Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to report earnings on November, 15.

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Ratings Coverage

Out of 2 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ritter Pharmaceuticals has been the topic of 3 analyst reports since December 2, 2015 according to StockzIntelligence Inc. The rating was initiated by Chardan Capital Markets on Wednesday, December 2 with “Buy”. Maxim Group initiated Ritter Pharmaceuticals Inc (NASDAQ:RTTR) on Thursday, April 14 with “Buy” rating. The firm earned “Buy” rating on Tuesday, October 25 by Chardan Capital Markets.

According to Zacks Investment Research, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California.”

RTTR Company Profile

Ritter Pharmaceuticals, Inc., incorporated on October 16, 2008, develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Firm conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment